Literature DB >> 23551950

Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis.

Stephan Dähnhardt-Pfeiffer1, Dorothee Dähnhardt, Matthias Buchner, Kersten Walter, Ehrhardt Proksch, Regina Fölster-Holst.   

Abstract

BACKGROUND: The skin barrier plays a crucial role in the pathophysiology of atopic dermatitis. The quality of the skin barrier can be assessed using a new semi-quantitative method to measure intercellular lipid lamellae. This procedure was used to evaluate the influence of the topical application of the calcineurin inhibitor tacrolimus 0.1% ointment (Protopic®) versus mometasone furoate cream (Ecural®) on the quality of the skin barrier. PATIENTS AND METHODS: 20 adult patients with active atopic dermatitis (SCORAD 10-63) were included in an open, non-interventional study. Lesions on their forearms were treated twice daily over 10 days with either tacrolimus 0.1% ointment or mometasone furoate cream. At the beginning and the end of the treatment period, SCORAD, TEWL and skin hydration were determined and the intercellular lipids were measured using transmission electron microscopy.
RESULTS: The SCORAD improved in both groups nearly to the same extent, whereas TEWL and skin hydration improved significantly only in the tacrolimus group. Using the semi-quantitative analysis of intercellular lipid length per 1,000 nm(2) intercellular space, a twofold increase for mometasone furoate cream and a fourfold increase for tacrolimus 0.1% ointment were determined.
CONCLUSIONS: In addition to its known antiinflammatory effect, tacrolimus 0.1% ointment leads also to a measurable increase of the lipids of the skin barrier in patients with atopic dermatitis, exceeding the effect of mometasone furoate cream.
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551950     DOI: 10.1111/ddg.12074

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  6 in total

Review 1.  [Epidermal barrier disorders in dermatoses].

Authors:  E Proksch; D Dähnhardt; R Fölster-Holst
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

2.  Reducing Radiation Dermatitis Using a Film-forming Silicone Gel During Breast Radiotherapy: A Pilot Randomized-controlled Trial.

Authors:  Songmi Ahn; Kihoon Sung; Hyun Ju Kim; Young Eun Choi; Young Kyu Lee; Jeong Soo Kim; Seul Ki Lee; Joo-Young Roh
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 3.  Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.

Authors:  Mamitaro Ohtsuki; Hiroshi Morimoto; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2018-06-21       Impact factor: 4.005

Review 4.  Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.

Authors:  Lisa A Beck; Michael J Cork; Masayuki Amagai; Anna De Benedetto; Kenji Kabashima; Jennifer D Hamilton; Ana B Rossi
Journal:  JID Innov       Date:  2022-04-26

Review 5.  Atopic dermatitis: a review of topical nonsteroid therapy.

Authors:  Ariana Papier; Lindsay C Strowd
Journal:  Drugs Context       Date:  2018-04-03

Review 6.  The infectious complications of atopic dermatitis.

Authors:  Vivian Wang; Juri Boguniewicz; Mark Boguniewicz; Peck Y Ong
Journal:  Ann Allergy Asthma Immunol       Date:  2020-08-07       Impact factor: 6.347

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.